SCHEMBL15210399

SCHEMBL15210399

COc1cc(-c2cc3nccc(-c4nnc(CCN)o4)c3o2)cc(OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MAPK1 P28482 4/20 0.41
TSHR P16473 2/20 0.41
PDE4C Q08493 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
HPGD P15428 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
CASP1 P29466 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
QPCT Q16769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16429199 0.83 PDE4C (0.47) KDM4EALDH1A1SMN1; SMN2MAPK1PDE4C
SCHEMBL15212654 0.81 PDE4C (0.41) KDM4EMAPK1TSHRPDE4CLMNA
SCHEMBL723093 0.80 PDE4C (0.55) KDM4EALDH1A1PDE4CHPGDL3MBTL1
SCHEMBL722937 0.79 FYN (0.48) PDE4CCYP1A1CYP1A2CYP1B1ADORA2A
SCHEMBL15220264 0.78 PDE4C (0.38) PDE4CCYP1A1CYP1A2CYP1B1
SCHEMBL721309 0.78 PDE4C (0.47) PDE4CCYP1A1CYP1A2CYP1B1ADORA2A
SCHEMBL10267310 0.77 PDE4C (0.44) KDM4EALDH1A1MAPK1PDE4CMAPT
SCHEMBL722839 0.76 PDE4C (0.51) KDM4EALDH1A1MAPK1PDE4CHPGD
SCHEMBL723374 0.76 PDE4C (0.39) PDE4CMAPTCYP1A1CYP1A2CYP1B1
SCHEMBL722497 0.76 PDE4C (0.47) PDE4CCYP1A1CYP1B1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US claimed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038527-A1 FUROPYRIDINE DERIVATIVES SYK, LYN, BTK KDM4E 469/4885ALDH1A1 2320/4885SMN1; SMN2 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.